Loading...
•
Dec 25, 2021
Hologic Q1 2022 Earnings Report
Hologic's first quarter results for fiscal year 2022 were announced, with revenue of $1.471 billion and GAAP diluted EPS of $1.95, significantly exceeding expectations.
Key Takeaways
Hologic reported a revenue of $1.471 billion, a decrease of 8.6% compared to the prior year, driven by lower sales of COVID-19 assays. However, excluding COVID-19 revenue, organic revenue grew by 9.0%. GAAP diluted EPS was $1.95, and non-GAAP diluted EPS was $2.17, both significantly exceeding expectations. The company also significantly increased its full-year revenue and EPS guidance.
Revenue was $1.471 billion, a decrease of 8.6% year-over-year, but significantly higher than company guidance.
Excluding COVID-19 revenue, organic revenue grew 9.0% year-over-year.
GAAP diluted EPS was $1.95, and non-GAAP diluted EPS was $2.17, both significantly exceeding expectations.
The company significantly increased its full-year revenue and EPS guidance.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Revenue by Segment
Diagnostics Revenue
CapyFin.comMolecular Diagnostics Revenue
CapyFin.comCytology & Perinatal Revenue
CapyFin.comBlood Screening Revenue
CapyFin.comBreast Health Revenue
CapyFin.comBreast Imaging Revenue
CapyFin.comInterventional Breast Solutions Revenue
CapyFin.comGYN Surgical Revenue
CapyFin.comSkeletal Health Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Hologic raised its full-year revenue and EPS guidance significantly, reflecting an increase to full-year revenue by $600 million and non-GAAP EPS by $1.35 at the midpoint.
Positive Outlook
- Upside from COVID-19 testing
- Organic growth in base Diagnostics business
- Organic growth in base Surgical businesses
Challenges Ahead
- Headwinds from supply chain challenges in Breast Health business
Revenue & Expenses
Visualization of income flow from segment revenue to net income